Home > Oncology > ELCC 2022 > Small Cell Lung Cancer > Outcomes of real-world CANTABRICO trial match results from CASPIAN

Outcomes of real-world CANTABRICO trial match results from CASPIAN

Presented By
Dr Dolores Isla, Hospital Clinico Universitario Lozano Blesa, Spain
Presented by
Dolores Isla Hospital Clinico Universitario Lozano Blesa, Spain
Conference
ELCC 2022
Trial
CANTABRICO
Doi
https://doi.org/10.55788/9f019f2f
Reflecting a broader patient population and treatment practices in Spain, the real-world CANTABRICO trial demonstrated a similar safety profile and clinical benefit of durvalumab/EP as those from the phase 3, randomised CASPIAN trial. Small cell lung cancer (SCLC) represents approximately 13% of all newly diagnosed lung cancers. Most patients with SCLC have extensive-stage disease (ES-SCLC) at presentation, and prognosis remains poor [1]. Recently, the phase 3 CASPIAN trial (NCT03043872) demonstrated an improved overall survival (OS) with durvalumab plus platinum-etoposide (EP) versus EP alone in treatment-naïve patients with ES-SCLC [2,3]. However, there is limited information on the efficacy and safety of this regime in, for example, patients with ECOG performance status 2, specific comorbidities, controlled autoimmune diseases, or patients where the physician c...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on